BI 853520, a FAK-Simile of Prior FAK Inhibitors?
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00621-z
Abstract: In this issue of Targeted Oncology, the BI 853520 investigators present three complementary studies of BI 853520 that investigate this drug in both Western and Eastern patient populations, as well as investigating the effects of… read more here.
Keywords: fak; kinase; defactinib; cancer ... See more keywords
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.tps505
Abstract: TPS505Background: Focal adhesion kinase (FAK) is consistently hyperactivated in pancreatic ductal adenocarcinoma (PDAC), and FAK signaling is a key driver in forming its fibrotic and proinflammatory tumor microenvironment. Inhibition of FAK signaling leads to significant… read more here.
Keywords: fak; defactinib; phase study; fak inhibitors ... See more keywords
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3087
Abstract: 3087 Background: The NCI-MATCH trial assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma to targeted therapies based on genetic alterations identified in tumor biopsies. Neurofibromatosis 2 (NF2)-inactivated tumors demonstrate increased sensitivity to FAK… read more here.
Keywords: response; defactinib; altered tumors; nf2 altered ... See more keywords